Table 1.
SVR Rates in Phase 3 Trials of Sofosbuvir‐based Regimens in Patients with HCV Genotype 1 (see references 6, 7, 8)
| Study | Population | Treatment | Duration | SVR12 Rates |
|---|---|---|---|---|
| ION‐1 | GT 1 treatment‐naïve, including 15.7 percent (136/865) with cirrhosis | SOF/LDV | 12 weeks | 97.7% (209/214) |
| SOF/LDV + RBV | 12 weeks | 97.2% (211/217) | ||
| SOF/LDV | 24 weeks | NA (n = 217) | ||
| SOF/LDV + RBV | 24 weeks | NA (n = 217) | ||
| ION‐2 | GT 1 treatment‐experienced, including 20.0 percent (88/440) with cirrhosis | SOF/LDV | 12 weeks | 93.6% (102/109) |
| SOF/LDV + RBV | 12 weeks | 96.4% (107/111) | ||
| SOF/LDV | 24 weeks | 99.1% (108/109) | ||
| SOF/LDV + RBV | 24 weeks | 99.1% (110/111) | ||
| ION‐3 | GT 1 treatment‐naïve | SOF/LDV | 8 weeks | 94.0% (202/215) |
| SOF/LDV + RBV | 8 weeks | 93.1% (201/216) | ||
| SOF/LDV | 12 weeks | 95.4% (206/216) |
SOF 400 mg once daily and LDV 90 mg once daily coformulated as a single pill; RBV weight‐based dosing twice daily.
Abbreviations: GT, genotype; LDV, ledipasvir; SOF, sofosbuvir.